Comparison of brain-reactive blood-markers with cognitive performance at baseline*
| Biomarker candidates | No-NCD-group (N=31) | NCD group (N-9) | p Value† |
|---|---|---|---|
| Anti-ds DNA antibodies % (n/N)‡ | 41.9% (13/31) | 55.6% (5/9) | 0.71 |
| Anti-GP1 IgG antibodies positivity % (n / N)‡ | 40% (6/15) | 0% (0/2) | 1.0 |
| Lupus anticoagulant positivity % (n / N)‡ | 26.7% (4/15) | 0% (0/2) | 1.0 |
| Antiribosomal P antibodies positivity % (n N)‡ | 46.7% (14/30) | 88.9% (8/9) | 0.05 |
| NR2 antibodies (U/mL) | 1.0 (0.8 to 1.3) | 0.7 (0.5 to 1.0) | 0.08 |
| NGAL (ng/mL) | 105.5 (83.8 to 132.8) | 121.8 (87.3 to 169.9) | 0.66 |
| S100B (pg/mL) | 24.6 (15.1 to 40.2) | 30.7 (15.7 to 59.7) | 0.53 |
| S100A8/A9 (ng/mL) | 929.4 (640.9 to 1347.7) | 1540.8 (827.7 to 2868.4) | 0.25 |
*Values are geo means (95% CI) of log-transformed biomarker concentrations in the serum, unless noted otherwise.
†p Values are from multivariate analysis adjusting for demographics and SLEDAI total score, except for the anti-dsDNA antibodies which excluded scores for these antibodies.
‡Differences in proportions were assessed for significant differences using Fisher's exact test.
NGAL, neutrophil gelatinase associated lipocalin; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index.